<DOC>
	<DOCNO>NCT02432326</DOCNO>
	<brief_summary>This open label , multi-center , phase 1 study BBI608 BBI503 administer orally combination patient advance solid tumor . The primary goal determine safety , tolerability , recommend phase II dose ( RP2D ) combination regimen .</brief_summary>
	<brief_title>A Study BBI608 BBI503 Administered Combination Adult Patients With Advanced Solid Tumors</brief_title>
	<detailed_description />
	<criteria>Inclusion Criteria 1 . Signed write informed consent must obtain document accord International Conference Harmonisation ( ICH ) local regulatory requirement 2 . A histologically cytologically confirm solid tumor metastatic , unresectable , recurrent standard therapy exist longer effective . Patients must consider eligible potentially curative resection 3 . ≥ 18 year age 4 . Measurable disease define Response Evaluation Criteria Solid Tumors ( RECIST ) 1.1 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 1 6 . Male female patient childproducing potential must agree use contraception avoidance pregnancy measure study 30 day last dose 7 . Females childbearing potential must negative serum pregnancy test 8 . Aspartate transaminase ( AST ) &lt; 2.5 x upper limit normal ( ULN ) alanine transaminase ( ALT ) ≤ 2.5 × ULN . 1 . Patients hepatocellular carcinoma liver lesion liver metastasis may eligible AST &lt; 3.5 x ULN AST &lt; 3.5 x ULN agree upon investigator medical monitor sponsor . 2 . Patients hepatocellular carcinoma may eligible provide AST ALT ≤ 5.0 x ULN . 9 . Hemoglobin ( Hgb ) ≥ 9 g/dL 10 . Total bilirubin ≤ 1.5 × ULN . Patients liver lesion hepatocellular carcinoma total bilirubin ≤ 2.0 x ULN may eligible agreed upon investigator medical monitor sponsor . 1 . Patients hepatocellular carcinoma may eligible provided total bilirubin ≤ 3.0 x ULN consider ChildPugh Class A ChildPugh Class B7 ( ChildPugh Class B total ChildPugh score exceed 7 ) . 2 . Patients Gilbert 's syndrome uncomplicated liver disease may eligible agreed upon investigator medical monitor sponsor . 11 . Creatinine ≤ 1.5 × ULN , patient creatinine level institutional upper limit normal , creatinine clearance must &gt; 60 mL/min/1.73 m^2 . 12 . Absolute neutrophil count ≥ 1.5 x 10^9/L 13 . Platelets ≥ 100 x 10^9/L ; patient hepatocellular carcinoma may enroll provided platelet count ≥ 75 x 10^9/L . 14 . Life expectancy ≥ 3 month Exclusion Criteria 1 . Anticancer chemotherapy , radiotherapy , immunotherapy , investigational agent within 7 day first dose BBI608 BBI503 . Patients may begin BBI608 BBI503 date determine investigator medical monitor sponsor minimum 7 day since last receiving anticancer treatment , provide treatmentrelated adverse effect resolve deem irreversible 2 . Surgery within 4 week prior first dose 3 . Any known untreated brain metastasis . Treated subject must stable 4 week completion treatment brain metastasis image document stability require . Patients must clinical symptom brain metastasis must either steroids stable dose steroid least 2 week prior protocol enrollment . Patients know leptomeningeal metastasis exclude , even treat 4 . Pregnant breastfeed 5 . Significant gastrointestinal disorder ( ) ( e.g. , active Crohn 's disease ulcerative colitis , history extensive gastric resection and/or small intestinal resection ) absorption oral medication impair . 6 . Unable unwilling swallow BBI608 and/or BBI503 capsule daily 7 . Prior treatment either BBI608 BBI503 8 . Uncontrolled concurrent illness include , limited ongoing active infection , clinically significant nonhealing heal wound , symptomatic congestive heart failure , unstable angina pectoris , cardiac arrhythmia , significant pulmonary disease ( shortness breath rest mild exertion ) , uncontrolled infection psychiatric illness/social situation would limit compliance study requirement 9 . Subjects history another primary cancer , exception : ) curatively resect nonmelanoma skin cancer ; b ) curatively treated cervical carcinoma situ ; c ) primary solid tumor ( know active disease present ) , opinion investigator , affect patient outcome set current diagnosis 1 . Patients adenocarcinoma unknown primary exclude 2 . Patients diagnosis two coexist primary cancer exclude 10 . Abnormal ECGs clinically significant QT prolongation ( QTc &gt; 480 msec ) , clinically significant cardiac enlargement hypertrophy , new bundle branch block exist leave bundle branch block , sign new , active ischemia . Patients evidence prior infarction New York Heart Association ( NYHA ) functional class II , III , IV exclude , patient mark arrhythmia Wolff Parkinson White pattern complete atrioventricular ( AV ) dissociation</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Neoplasms</keyword>
</DOC>